Avoid common mistakes on your manuscript.
Sirs,
The ability to distinguish between sporadic presentations of hereditary spastic paraparesis (HSP) and primary lateral sclerosis (PLS) is important in terms of prognostication and genetic counseling, but clinical differentiation is problematic [6]. Primary lateral scherosis is a sporadic disorder of progressive spino-bulbar spasticity and may be part of the clinical spectrum of amyotrophic lateral sclerosis (ALS) [10]. Hereditary spastic paraparesis is a clinically and genetically heterogeneous group of disorders characterized by a slowly progressive spastic paraparesis [8, 12].
To date, 15 genes and more than 20 additional loci have been identified for autosomal dominant (AD), autosomal recessive and X-linked forms of HSP [5, 7]. The spastin gene (SPG4) mutation is the most frequent cause of AD HSP (around 40% of families) and is also frequent in sporadic HSP (13%), but not in PLS [3]. We recently found pathogenic paraplegin gene (SPG7) mutations 11% of patients with sporadic HSP [4]. The role of other HSP genes in sporadic upper motor neuron (UMN) syndromes is largely unknown. Two known mutations (c.263G>A/p.N88S and c.269C>T/p.S90L) in exon 3 of the seipin/BSCL2 gene (SPG17) can cause a range of AD (mixed) upper and lower motor neuron disorders, including Silver syndrome (HSP with amyotrophy of the hands), variants of Charcot–Marie-tooth disease type 2, distal hereditary motor neuropathy type V (dHMNV), but also pure and complicated forms of HSP [1, 13, 14]. Because of incomplete penetrance, the seipin/BSCL2 mutation can manifest as a sporadic disease [14].
To investigate whether these two seipin/BSCL2 mutations are present in patients with sporadic HSP and PLS, we screened exon 3 of the seipin/BSCL2 gene in 86 Dutch patients with a sporadic adult-onset UMN syndrome. Inclusion criteria were a gradually progressive UMN syndrome, adult-onset, disease duration >6 months and a negative family history. Exclusion criteria were lower motor neuron loss meeting the revised El Escorial criteria for clinically definite, clinically probable or probable laboratory-supported ALS [2] and evidence of other causes of a UMN syndrome based on a battery of laboratory investigations, including serum biochemistry (including thyroid-stimulating hormone, angiotensin converting enzyme, vitamin B12, folate and vitamin E), analysis of very long chain fatty acids in plasma, serology (syphilis, borreliosis, human T cell lymphotrophic virus type 1 and human immunodeficiency virus) and bile alcohol analysis in urine, and cerebral and spinal magnetic resonance imaging (MRI). The presence of the SPG4 and SPG7 mutations was excluded in all patients. The study was approved by the medical ethics review board of the University Medical Center in Utrecht, and written informed consent was obtained from all patients.
Mutation screening of the seipin/BSCL2 gene was performed using automated forward and reverse direct sequencing of exon 3. The BSCL2 exon 3 was amplified by PCR using intronic primers (primer sequences available on request), and the PCR products were loaded on an Applied Biosystems 3730 DNA Analyzer (Applied Biosystems, Foster City, CA). Sequence data were analyzed using Phred-PolyPhred software (CodonCode, Dedham, WA) and compared to the BSCL2 reference sequence (GenBank accession number NM_032667).
Clinical characteristics of the 86 included patients are shown in Table 1. No exon 3 mutations were detected. A previously reported, non-pathogenic polymorphism (c.294+11 G>T) [11] was identified in 27 patients (Table 2). This allele frequency is consistent with a previous report [11] and with our own data (minor allele frequency of c.294+11 G>T of 0.20 in 50 unrelated reference samples from unaffected individuals).
We did not search for seipin/BSCL2 mutations outside of exon 3. Results from previous studies, however, suggest that the c.263G>A (p.N88S) and c.269C>T (p.S90L) mutations in exon 3 are probably the only two seipin/BSCL2 mutations associated with Silver syndrome and distal hereditary motor neuropathy type V and that, therefore, seipin/BSCL2 mutation analysis for these disorders may be restricted to exon 3 [11]. Both of these exon 3 mutations destroy a predicted N-glycosylation site of the seipin protein, which probably causes the accumulation of the misfolded mutant seipin in the endoplasmic reticulum (ER), leading to cell death as a result of ER stress [9].
Our population included 40 patients with a phenotype of spastic paraparesis similar to pure HSP. In families with the seipin/BSCL2 mutation, the frequency of an HSP phenotype has been observed to be as high as 10% of patients [1]. The other 46 patients in our study had symptomatic UMN involvement of the arms or bulbar region, which may suggest a diagnosis of PLS [6, 10]. The results of our study indicate that the seipin/BSCL2 exon 3 mutations are not a common cause of sporadic pure HSP and PLS. Therefore, they do not support inclusion of the Seipin/BSCL2 gene in the group of first-choice HSP genes to screen for mutations during the diagnostic work-up of sporadic HSP and PLS.
References
Auer-Grumbach M, Schlotter-Weigel B, Lochmuller H, Strobl-Wildemann G, Auer-Grumbach P, Fischer R, Offenbacher H, Zwick EB, Robl T, Hartl G, Hartung HP, Wagner K, Windpassinger C (2005) Phenotypes of the N88S Berardinelli–Seip congenital lipodystrophy 2 mutation. Ann Neurol 57:415–424
Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293–299
Brugman F, Wokke JH, Scheffer H, Versteeg MH, Sistermans EA, van den Berg LH (2005) Spastin mutations in sporadic adult-onset upper motor neuron syndromes. Ann Neurol 58:865–869
Brugman F, Scheffer H, Wokke JHJ, Nillesen WM, de Visser M, Aronica E, Veldink JH, van den Berg LH (2008) Paraplegin mutations in sporadic adult-onset upper motor neuron syndromes. Neurology 71:1500–1505
Dick KJ, Al-Mjeni R, Baskir W, Koul R, Simpson MA, Patton MA, Raeburn S, Crosby AH (2008) A novel locus for an autosomal recessive hereditary spastic paraplegia (SPG35) maps to 16q21–q23. Neurology 71:248−52
Fink JK (2001) Progressive spastic paraparesis: hereditary spastic paraplegia and its relation to primary and amyotrophic lateral sclerosis. Semin Neurol 21:199–207
Fink JK (2003) The hereditary spastic paraplegias: nine genes and counting. Arch Neurol 60:1045–1049
Harding AE (1981) Hereditary “pure” spastic paraplegia: a clinical and genetic study of 22 families. J Neurol Neurosurg Psychiatr 44:871–883
Ito D, Suzuki N (2007) Molecular pathogenesis of seipin/BSCL2-related motor neuron diseases. Ann Neurol 61:237–250
Pringle CE, Hudson AJ, Munoz DG, Kiernan JA, Brown WF, Ebers GC (1992) Primary lateral sclerosis Clinical features, neuropathology and diagnostic criteria. Brain 115:495–520
Rohkamm B, Reilly MM, Lochmuller H, Schlotter-Weigel B, Barisic N, Schols L, Nicholson G, Pareyson D, Laura M, Janecke AR, Miltenberger-Miltenyi G, John E, Fischer C, Grill F, Wakeling W, Davis M, Pieber TR, Auer-Grumbach M (2007) Further evidence for genetic heterogeneity of distal HMN type V, CMT2 with predominant hand involvement and Silver syndrome. J Neurol Sci 263:100–106
Salinas S, Proukakis C, Crosby A, Warner TT (2008) Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol 7:1127–1138
van de Warrenburg BP, Scheffer H, van Eijk JJ, Versteeg MH, Kremer H, Zwarts MJ, Schelhaas HJ, van Engelen BG (2006) BSCL2 mutations in two Dutch families with overlapping Silver syndrome-distal hereditary motor neuropathy. Neuromuscul Disord 16:122–125
Windpassinger C, Auer-Grumbach M, Irobi J, Patel H, Petek E, Horl G, Malli R, Reed JA, Dierick I, Verpoorten N, Warner TT, Proukakis C, Van den BP, Verellen C, Van Maldergem L, Merlini L, De Jonghe P, Timmerman V, Crosby AH, Wagner K (2004) Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nat Genet 36:271–276
Open Access
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Brugman, F., Scheffer, H., Schelhaas, H.J. et al. Seipin/BSCL2 mutation screening in sporadic adult-onset upper motor neuron syndromes. J Neurol 256, 824–826 (2009). https://doi.org/10.1007/s00415-009-5009-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-009-5009-6